WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (AMEX: ILI) today reported financial results for its year-end 2006 and fourth quarter ended December 31, 2006. The Company reported revenues of $4.7 million and a net loss of $6.9 million, or $(0.27) per basic and diluted common share, for the year ended December 31, 2006 and revenues of $1.8 million and a net loss of $2.6 million, or $(0.10) per basic and diluted common share, for the quarter ended December 31, 2006. Interleukin Genetics’ reported revenues resulted from the processing of genetic assessment tests launched in the first quarter of 2006 for cardiovascular health risk and general nutrition, and from sales of nutritional supplement products in food, drug, and mass retail outlets through its subsidiary, the Alan James Group, since it was acquired in August of 2006.
